A strategy inspired by deficient HIV replication could be used as a treatment to reduce viral load in patients living with HIV and help control the pandemic of the retrovirus. Scientists from the University of California San Francisco want to use HIV against itself by using a parasitic version of the pathogen. Read More
China’s Genor Biopharma Co. Ltd. agreed to out-license GB-261, its bispecific antibody candidate primarily targeting B-cell lymphomas, to TRC 2004 Inc., a U.S.-based newco co-founded by Third Rock Ventures LLC and Two River Group Holdings LLC. Read More
Piplartine, also called piperlongumine, had protective effects against hearing loss induced by aminoglycoside antibiotics in zebrafish and mouse models of kanamycin-induced hair cell loss. Kanamycin is a member of the aminoglycosides, a group of antibiotics that have broad-spectrum activity against gram-negative bacteria, including multidrug resistant strains. Read More
Esculetin, also known as 6,7-dihydroxycoumarin, is a coumarin-derived phytochemical that has shown effects against ischemic stroke. Additionally, chemokine-like factor 1 (CKLF1) has been revealed in previous findings to be a target for stroke when using coumarin-derived compounds. The effects of esculetin and the potential involvement of CKLF1 were tested in photothrombotic stroke in mice. Read More
Aligos Therapeutics Inc. has described programmed cell death 1 (PDCD1; PD-1; CD279)/PD-1 ligand 1 (PD-L1; CD274) interaction inhibitors reported to be useful for the treatment of liver cancer (hepatocellular carcinoma) and hepatitis B. Read More
Kano Therapeutics Inc. announced it has secured $5 million in seed funding, bringing its total funding to date to $7.1 million. The company plans to use the funding to begin internal pipeline development of ex vivo genetic medicines based on kilobase gene insertion, expand its existing therapeutic collaborations to initiate externally driven preclinical programs, and scale its production capacity. Read More
From no hope to viable treatments, BioWorld is there to cover the breakthroughs in medicine. Listen to Randy Osborne explain why the BioWorld team is ‘always on the lookout for what's next.’ Read More
Zeno Management Inc. has divulged GTPase KRAS (mutant) inhibitors (particularly, KRAS (G12C mutant)) reported to be useful for the treatment of cancer. Read More
Shanghai Zedeman Pharmaceutical Technology Co. Ltd. has identified aryl hydrocarbon receptor (AhR) agonists reported to be useful for the treatment of autoimmune disease, cancer, diabetes, eye disorders, viral infections, psoriasis, and inflammatory and neurological disorders, among others. Read More
Liver fibrosis still lacks effective therapy; hepatic stellate cells (HSCs) are the primary fibrogenic cell type activated during liver injury. To date, almost half of the drugs used for liver treatment are natural product derivatives. Read More
Otsuka Pharmaceutical Co. Ltd. has disclosed antibody-drug conjugates comprising humanized monoclonal antibody targeting syndecan-1 (SDC1; SYND1; CD138) covalently linked to anticancer and/or cytotoxic agents through linkers reported to be useful for the treatment of cancer. Read More
